Gynecologic Cancers

P=N/A, N=75, Recruiting, Universität Duisburg-Essen | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2026 --> Dec 2027

P=N/A, N=72, Completed, Travera Inc | Recruiting --> Completed | N=200 --> 72 | Trial completion date: Jul 2028 --> Mar 2026 | Trial primary completion date: Jul 2027 --> Mar 2026

P=N/A, N=7000, Recruiting, University Health Network, Toronto

Notably, antioxidant levels showed inverse correlations with several oxidative markers, and lower levels of glutathione and vitamin C were independently linked to higher endometrial cancer risk. These findings suggest that redox imbalance plays a critical role in endometrial carcinogenesis and that antioxidant profiles may aid in risk assessment and early detection strategies.

In addition, vvDD-nsmDR-18 treatment was associated with expansion of CD39+CD103+CD8+ tumor-reactive T cells and a shift toward a lower PD-1 expression phenotype within this population. These findings demonstrate that nsmDR-18-expressing oncolytic viruses can remodel the immunosuppressive landscape of advanced ovarian cancer, suggesting this approach is a promising candidate for further clinical development.

MIRV-related ocular alterations are frequent but reversible and clinically manageable. Multimodal imaging combined with functional and refractive assessment provides sensitive markers of corneal epithelial toxicity and supports integrated ophthalmologic monitoring to preserve visual function and maintain oncologic treatment continuity.

Pembrolizumab plus weekly paclitaxel, with or without bevacizumab, significantly improved progression-free survival and overall survival in participants with platinum-resistant recurrent ovarian cancer who had received one to two previous systemic regimens, supporting this regimen as a new treatment option for this population.

P=N/A, N=1800, Recruiting, The New York Proton Center | Trial completion date: Jan 2027 --> Jan 2028 | Trial primary completion date: Jan 2027 --> Jan 2028

P=N/A, N=58, Recruiting, Hamilton Health Sciences Corporation | Not yet recruiting --> Recruiting | Trial completion date: Jun 2026 --> Nov 2026 | Trial primary completion date: Sep 2025 --> May 2026

We posit that female immune pathologies, ranging from systemic autoimmunity to gynecologic malignancies, represent a context-dependent dysregulation or co-option of this metabolic calibration. Ultimately, we discuss the clinical necessity of transitioning from generic biotic interventions toward Sexual Dimorphic Metabotyping, providing a precision framework to restore physiological tolerance and manage sex-biased immune pathologies.

With subsequent trastuzumab deruxtecan (T-Dxd) treatment, she achieved a complete and durable response and remains with no evidence of disease after one year of follow-up. This report underscores the potential utility of HER2-directed therapy in select cases of vulvar carcinoma and emphasizes the importance of molecular profiling in rare gynecologic neoplasms.

This systematic review examines the crucial role of BRCA1 and BRCA2 in DNA repair, as well as how their mutations contribute to the development of inherited gynecological malignancies, and potential treatments targeting BRCA-deficient tumors. Also discusses resistance mechanisms to PARP inhibitors, the potential for combination therapies (PARP inhibitors + immune checkpoint inhibitors), and Advances in nanotechnology-based drug delivery, dynamic biomarker development, and CRISPR-based gene repair for BRCA mutations as future challenges and direction for curable patient.